Educate About Nirsevimab to Prevent RSV

You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.

RSV is the most common cause of hospitalization in U.S. infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.

Nirsevimab is a monoclonal antibody given IM in the clinic or hospital...similar to palivizumab (Synagis). You’ll hear some people call nirsevimab a vaccine...since it’s a form of passive immunization.